Treatment of Pneumocystis Pneumonia of Mild-to-Moderate Severity (Alveolar-Arterial Oxygen Gradient ≤4.7 kPa)
Pneumocystis pneumonia (PCP) presents across a spectrum of severity. When the alveolar-arterial (A-a) oxygen gradient is 4.7 kPa or less at presentation, the episode is classified as mild-to-moderate — a distinction that directly shapes the treatment approach and the setting of care.
PCP severity is stratified by the A-a O₂ gradient: a gradient of ≤4.7 kPa defines mild-to-moderate disease, while a gradient of >4.7 kPa places the patient in the moderate-to-severe category. Correct classification at presentation is essential, as it determines both the route of treatment and the required level of monitoring.
The primary goal is clinical improvement with improvement of oxygenation. Response is formally reassessed between days 4 and 8 of treatment. Failure is defined as a lack of improvement — or worsening — of oxygenation during this window.
References
- the severity of PCP can be classified as mild-to-moderate if ≤4.7 kPa or moderate-to-severe if >4.7 kPa (Table 1).
- We recommend trimethoprim-sulfamethoxazole as the first-line treatment of choice for PCP of any severity (Grade 1A).
- Patients with mild-to-moderate PCP may be treated with oral therapy as an outpatient with close clinical monitoring.
- We suggest waiting at least 4 days before switching therapy in the absence of clinical improvement (Grade 2C).
- Treatment failure is defined as a lack of improvement or worsening of oxygenation with/without worsening of chest radiographic appearances between days 4 and 8 of anti-Pneumocystis treatment.